Submitted by Anjali Fortna on Tue, 05/26/2015 - 2:43pm 1. Currently, how confident are you in your * 1=NOT at all confident, 2=Somewhat confident, 3=Confident, 4=Very confident, 5=EXTREMELY confident, N/A=Not within the scope of my practice 12345 Understanding of recent clinical trial data for patients with ACS? Understanding of recent clinical trial data for patients with ACS? - 1 Understanding of recent clinical trial data for patients with ACS? - 2 Understanding of recent clinical trial data for patients with ACS? - 3 Understanding of recent clinical trial data for patients with ACS? - 4 Understanding of recent clinical trial data for patients with ACS? - 5 Ability to develop personalized treatment plans to effectively address risk-benefit considerations to improve overall quality of life in patients with ACS? Ability to develop personalized treatment plans to effectively address risk-benefit considerations to improve overall quality of life in patients with ACS? - 1 Ability to develop personalized treatment plans to effectively address risk-benefit considerations to improve overall quality of life in patients with ACS? - 2 Ability to develop personalized treatment plans to effectively address risk-benefit considerations to improve overall quality of life in patients with ACS? - 3 Ability to develop personalized treatment plans to effectively address risk-benefit considerations to improve overall quality of life in patients with ACS? - 4 Ability to develop personalized treatment plans to effectively address risk-benefit considerations to improve overall quality of life in patients with ACS? - 5 2. The PEGASUS-54 Trial enrolled 20,000 patients with acute myocardial infarction. Which of the following was NOT required for a patient to enroll in the trial? * 1-3 years out from an MI Additional atherothrombotic risk factor Low bleeding risk Participated in the CHARISMA trial 3. Which of the following was not shown in the DAPT trial subgroup of patients with ACS who had stents? * Large reductions in ischemic events Large reductions in MI’s and spontaneous MI’s Large reductions in stent thrombosis Large reductions in bleeding 4. Recent clinical trial data suggests that which of the following therapies plus aspirin reduces the frequency of ischemic stroke without an excess in fatal bleeding or intracranial hemorrhage? * Ticagrelor 90 mg 2x/day + aspirin Ticagrelor 60 mg 2x/day + aspirin Both a and b None of the above 5. Some modest trials have seen a benefit with aspiration thrombectomy during primary PCI of STEMI. Data from the larger _____ and _____ trials did not show mortality reduction; therefore the pooled data from the smaller trials is invalid. * TASTE; TOTAL TASTE; ATLANTIC TASTE; ACCOAST TOTAL; ATLANTIC 6. Please indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with ACS. You will not be graded on your responses. * (1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable to me) 12345N/A Utilize risk score tools in the clinical decision making for patients with ACS Utilize risk score tools in the clinical decision making for patients with ACS - 1 Utilize risk score tools in the clinical decision making for patients with ACS - 2 Utilize risk score tools in the clinical decision making for patients with ACS - 3 Utilize risk score tools in the clinical decision making for patients with ACS - 4 Utilize risk score tools in the clinical decision making for patients with ACS - 5 Utilize risk score tools in the clinical decision making for patients with ACS - N/A Individually evaluate risk of bleeding complication weighed against the clinical benefit Individually evaluate risk of bleeding complication weighed against the clinical benefit - 1 Individually evaluate risk of bleeding complication weighed against the clinical benefit - 2 Individually evaluate risk of bleeding complication weighed against the clinical benefit - 3 Individually evaluate risk of bleeding complication weighed against the clinical benefit - 4 Individually evaluate risk of bleeding complication weighed against the clinical benefit - 5 Individually evaluate risk of bleeding complication weighed against the clinical benefit - N/A Apply early invasive management strategies, even for high-risk patients Apply early invasive management strategies, even for high-risk patients - 1 Apply early invasive management strategies, even for high-risk patients - 2 Apply early invasive management strategies, even for high-risk patients - 3 Apply early invasive management strategies, even for high-risk patients - 4 Apply early invasive management strategies, even for high-risk patients - 5 Apply early invasive management strategies, even for high-risk patients - N/A Leave this field blank
